Styrelse — Gabather
Gedea Biotech - The Swedish Life Science Industry
Gedea Biotech AB Medicon Village 223 81 Lund Sverige. Annette Säfholm, VD annette.safholm@gedeabiotech.com +46 (0) 708 - 91 86 81 Integritetspolicy. Nyhetsbrev Gedea Biotech bidrar i hög grad till tre av FN:s globala mål: Uppnå jämställdhet mellan könen och stärka kvinnor och flickor Kvinnors och flickors medverkan i samhället underlättas av god hälsa. Gedea Biotech – Gedea Biotech received €3 million from the EU program Fast Track to Innovation to fund completion of the clinical trial program and preparation work for market introduction of the company’s antibiotic-free treatment for vaginal infections. Gedea Biotech startades av ett tvärvetenskapligt team från Lunds Universitet.
Everything points towards pHyph reaching its potential in achieving an attractive position in a market with high medical needs. Gedea Biotech has announced that all patients have been recruited for the multi-center study evaluating the clinical performance of an antibiotic-free treatment for vaginal infections. This pilot study marks the start of a clinical development program of a treatment with dual effect, targeting both vaginal bacterial and fungal infections. Gedea Biotech reports that all 24 patients have been treated with its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis in a proof of concept clinical study.
Gedea Biotech AB utvecklar en antibiotikafri behandling av vaginala infektioner, orsakade av bakterier (bakteriell vaginos, BV). Behandlingseffekten är motsvarande den för antibiotika, som är den vanligaste behandlingen idag. Gedeas mål är att pHyph ska bli den första antibiotikafria produkten som effektivt förebygger och behandlar BV. Gedea Biotech is a Swedish, innovative women’s health company developing pHyph, the first antibiotic free treatment that both prevents and treats bacterial vaginosis. Vaginal infections affect at least 400 million women every year worldwide and the market is worth over $ 1.5 billion.
BioStock Live in Copenhagen - Gedea Biotech - YouTube
Gedea Biotech developes pHyph to treat and prevent recurrence of bacterial vaginosis. Bacterial vaginosis (BV) is a very common condition with a prevalence of 10-30% for women of childbearing age. The symptoms can very disturbing and include an often profuse thin, white, “fishy” smelling vaginal discharge, in the absence of itching. Köp aktier i Active Biotech - enkelt och billigt hos Avanza Bank.
Gedea Biotech bland de bästa startups i Europa LU Innovation
Gedea Biotech’s substance, GA101, is a natural substance that has always been part of our environment and is approved as a food additive. It acts by a novel mechanism that prevents and treats infection in depth by inhibiting the formation of biofilm. […] Köp aktier i Edesa Biotech Inc - enkelt och billigt hos Avanza Bank.
For Gedea Biotech, sustainability is a core activity – not posturing. Gedea Biotech developes pHyph to treat and prevent recurrence of bacterial vaginosis. Bacterial vaginosis (BV) is a very common condition with a prevalence of 10-30% for women of childbearing age. The symptoms can very disturbing and include an often profuse thin, white, “fishy” smelling vaginal discharge, in the absence of itching. Köp aktier i Active Biotech - enkelt och billigt hos Avanza Bank.
Adobe audition remove background noise
Gedea Biotech AB har organisationsnummer 559000-7026. Gedea Biotech har säte i Lund. Det går bra att ta kontakt med Gedea Biotech AB … Gedea Biotech arbetar för att följa vårdens utveckling mot en mer hållbar framtid. Det gör vi delvis genom att ta fram en behandling som är säker att använda och följer alla vetenskapliga processer och regler. Att p Hyph är fri från antibiotika spelar också en viktig roll för framtidens behandling av bakteriell vaginos.
pHyph is being developed to both cure bacterial vaginosis and prevent recurrence. Gedea Biotech, a biotech company started by a multidisciplinary team from Lund University, that develops an antibiotic-free treatment for vaginal infections named pHyph. pHyph can be used to treat vaginal thrush and bacterial vaginosis. Vaginal infections, such as vaginal thrush and bacterial vaginosis, are caused by fungi and bacteria growing under a biofilm and furthermore alter the natural pH of the vagina. Gedea Biotech develops an antibiotic-free treatment for vaginal bacterial infections; bacterial vaginosis (BV).
Freds och konfliktstudier
pHyph has been shown to have an excellent medical effect.A total of 82% of the subjects were clinically cured of bacterial vaginosis by day seven. pHyph is being developed to both cure bacterial vaginosis and prevent recurrence. Gedea Biotech, a biotech company started by a multidisciplinary team from Lund University, that develops an antibiotic-free treatment for vaginal infections named pHyph. pHyph can be used to treat vaginal thrush and bacterial vaginosis.
Gedea Biotech AB Medicon Village 223 81 Lund Sverige. Annette Säfholm, VD annette.safholm@gedeabiotech.com +46 (0) 708 - 91 86 81 Integritetspolicy.
Alertenterprise glassdoor
kvik halmstad avstånd
croser
vad betyder msek
anknytningsteori hemligheten
Är du vårt nästa succébolag inom Life Science? - almi invest
pHyph intends be the first antibiotic-free product that effectively prevents and treats bacterial vaginosis. Om Gedea Biotech. Gedea Biotech är ett svenskt, innovativt företag inom kvinnohälsa som utvecklar pHyph, en antibiotikafri och effektiv behandling av bakteriell vaginos. Vaginala infektioner drabbar mer än 400 miljoner kvinnor varje år över hela världen och marknaden är värd över 1,5 miljarder dollar.